Aberrantly glycosylated IgA molecules downregulate the synthesis and secretion of vascular endothelial growth factor in human mesangial cells

被引:43
作者
Amore, A
Conti, G
Cirina, P
Peruzzi, L
Alpa, M
Bussolino, F
Coppo, R
机构
[1] Regina Margherita Hosp, Dept Nephrol & Dialysis, Turin, Italy
[2] Univ Turin, CMID Immunopathol Ctr, Turin, Italy
[3] Univ Turin, Inst Canc Res & Treatment, Turin, Italy
[4] Univ Turin, Dept Genet Biol & Biochem, Turin, Italy
关键词
vascular endothelial growth factor (VEGF); nitric oxide (NO); mesangial cells (MCs); immunoglobulin A (IgA) nephropathy; abnormally glycosylated immunoglobulin A (IgA); degalactosylated immunoglobulin A (deGal IgA); desialylated immunoglobulin A (deSia IgA);
D O I
10.1053/ajkd.2000.19840
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
To gain insight into the glomerular capillary repair mechanisms in immunoglobulin A (IgA) nephropathy, we focused on vascular endothelial growth factor (VEGF-A) and nitric oxide (NO). Because abnormal glycosylation of serum IgA has been shown in IgA nephropathy, we examined whether VEGF-A and NO production by mesangial cells (MCs) could be modulated by aberrantly glycosylated (desialylated or degalactosylated) IgA. VEGF-A and NO synthase (NOS) gene expression were examined by reverse-transcriptase polymerase chain reaction (RT-PCR) or Northern blot analysis, and VEGF-A peptide, by capture enzyme-linked immunosorbent assay and NOS activity as production of tritium ([H-3]) citrulline from [H-3] arginine. Semiquantitative densitometric analysis of RT-PCR experiments showed a significant downregulation of VEGF-A messenger RNA (mRNA) in MCs incubated with aberrantly glycosylated IgA. This resulted in decreased release of VEGF-A in culture medium (P < 0.01). NOS activity and inducible NOS (iNOS) mRNA were enhanced by aberrantly glycosylated IgA (both P < 0.01). No modulation of constitutive NOS mRNA was found. The depression of the VEGF-A production induced by aberrantly glycosylated IgA was mediated by NO because it was completely reversed by the NOS inhibitor, No-nitro-L-arginine methyl ester. The NO donor, sodium nitroprusside, induced a bimodal modulation of VEGF; although low concentrations (0.0001 nmol/L) increased VEGF-A synthesis, greater concentrations (1,000 nmol/L) depressed it. In conclusion, we report negative control of VEGF-A synthesis in MCs by aberrantly glycosylated IgA, mediated by enhanced iNOS activity. We speculate that both increased iNOS activity and depressed VEGF-A synthesis might have a role in impairing vascular repair and favor sclerosis in IgA nephropathy. (C) 2000 by the National Kidney Foundation, Inc.
引用
收藏
页码:1242 / 1252
页数:11
相关论文
共 45 条
[21]  
Groene Hermann-Josef, 1995, Journal of Pathology, V177, P259
[22]  
GROENE HJ, 1995, NEPHROL DIAL TRANSPL, V9, P761
[23]   NITRIC-OXIDE - PATHOPHYSIOLOGICAL MECHANISMS [J].
GROSS, SS ;
WOLIN, MS .
ANNUAL REVIEW OF PHYSIOLOGY, 1995, 57 :737-769
[24]  
Hiki Y, 1996, J AM SOC NEPHROL, V7, P955
[25]  
Hood JD, 1998, AM J PHYSIOL-HEART C, V274, pH1054
[26]   Vascular endothelial growth factor vascular permeability factor produces nitric oxide-dependent hypotension - Evidence for a maintenance role in quiescent adult endothelium [J].
Horowitz, JR ;
Rivard, A ;
vanderZee, R ;
Hariawala, M ;
Sheriff, DD ;
Esakof, DD ;
Chaudhry, GM ;
Symes, JF ;
Isner, JM .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (11) :2793-2800
[27]   HUMAN MESANGIAL CELLS AND PERIPHERAL-BLOOD MONONUCLEAR-CELLS PRODUCE VASCULAR-PERMEABILITY FACTOR [J].
IIJIMA, K ;
YOSHIKAWA, N ;
CONNOLLY, DT ;
NAKAMURA, H .
KIDNEY INTERNATIONAL, 1993, 44 (05) :959-966
[28]  
IRUELAARISPE L, 1995, AM J PATHOL, V147, P1715
[29]   THE GLOMERULAR RESPONSE TO INJURY - PROGRESSION OR RESOLUTION [J].
JOHNSON, RJ ;
MADIAS, NE ;
KATES, D ;
LEWIS, E ;
COUSER, WG ;
BOMSZTYK, K ;
ANDRESS, DL ;
ALPERS, C ;
YOUNG, B ;
HUGO, C .
KIDNEY INTERNATIONAL, 1994, 45 (06) :1769-1782
[30]   Vascular endothelial growth factor is an essential molecule for mouse kidney development: Glomerulogenesis and nephrogenesis [J].
Kitamoto, Y ;
Tokunaga, H ;
Tomita, K .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (10) :2351-2357